Extracellular Vesicles in Peripheral Blood: Potential Biomarkers for Preclinical Alzheimer Disease
Kenneth A. Livingston Introduction: Disease-modifying interventions for Alzheimer Disease (AD) are suspected to be most efficacious in the earliest and asymptomatic, or preclinical, phase of the disease.1 To date, methods for reliably detecting pathologic changes of AD – mainly β-amyloid deposition in the brain – are invasive and expensive, requiring…